An observational study in Arterial Bleed, Pulmonary Arteriovenous Malformation and Embolization, sponsored by Okami Medical, Inc.. Enrolling by invitation at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Okami Medical, Inc. · Observational
This registry will provide insights into the use of Okami Medical devices in real-world clinical and study effectiveness and safety of Okami Medical devices.
1,383 studies on the registry are indexed under Hemorrhage; 244 are open to participants now.
This study's planned enrollment of 500 is above the median of 215 across 397 observational studies indexed under Hemorrhage.
Browse Hemorrhage studies →This is the only study on the registry with Okami Medical, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with a clinical condition treated with LOBO Vascular Occlusion System
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated for the control of peripheral arterial bleeding/hemorrhage.
Device: LOBO Vascular Occlusion System
Patients treated for pulmonary arteriovenous malformations.
Device: LOBO Vascular Occlusion System
Patients treated with the LOBO Vascular Occlusion System.
Device: LOBO Vascular Occlusion System
LOBO Vascular Occlusion System
Safety Endpoint
Incidence of device-related serious adverse events during the index procedure
Time frame: 30 days post-index procedure
Effectiveness Endpoint
Technical success of the LOBO Vascular Occlusion System defined as occlusion of the intended target(s) with the LOBO occluder, assessed by angiography
Time frame: During index procedure
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.